Structure Therapeutics Inc. (GPCR)
Structure Therapeutics develops oral small molecule drugs that target G protein coupled receptors to treat chronic diseases, mainly obesity. It last closed at $18.17 on Nov 17, down 2.15% on the day. In the past 30 days there were 1 dark pool print totaling $500K, the largest $500K.
Key Stats
Last 12 monthsNot reported for this period.
From GPCR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 7 | Citigroup | Maintained | Buy | $97 |
| Aug 7 | Citizens | Maintained | Buy | $110 |
| Jun 11 | HC Wainwright & Co. | Maintained | Buy | $70 |
| Apr 27 | Canaccord Genuity | Initiated | Buy | $101 |
Technical Analysis
The stock is 14% below its 20 day and 48% below its 50 day average. It is 147% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $17.86, and the nearest resistance the Pivot at $18.23.
| RSI (14) | 27.56 | Oversold below 30 | Oversold |
| MACD | -2.15 | Above its signal line | Bullish |
| Stochastic | 14.4 | Near the bottom of its range | Oversold |
| ADX (14) | 52.8 | Strong downtrend | |
| Williams %R | -93.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -198.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −10.7% | Change over 10 sessions | Bearish |
| ATR (14) | $1.47 | Typical daily range, 8.1% of price |
| RSI (14) | 25.78 | Oversold below 30 | Oversold |
| MACD | -7.87 | Below its signal line | Bearish |
| Stochastic | 2.9 | Near the bottom of its range | Oversold |
| ADX (14) | 29.0 | Trending down | |
| Williams %R | -99.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -104.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −53.0% | Change over 10 sessions | Bearish |
| ATR (14) | $5.01 | Typical daily range, 27.6% of price |
What happened before
See how GPCR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GPCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in GPCR in the last 90 days.
Dark Pool
30DGPCR Institutional Ownership
Full report →- ▼75 buying vs 106 selling
- ●Held by funds +0.2 pts
- ▼Funds holding -23
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 171 | 194 | −11.9% |
| In funds' top 10 | 2 | 8 | −75.0% |
| Held by funds | 31.6% | 31.5% | +0.2 pts |
| New / increased | 26 / 49 | 29 / 76 | −28.6% |
| Reduced / sold out | 61 / 45 | 49 / 34 | +27.7% |
| Put/call ratio | 0.01 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GPCR is in one of them and how their past GPCR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GPCR in an article yet. Here's the latest on the wider market.
GPCR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Tom CarperD · DE | Sell | $1K – $15K | Oct 4, 2023 | Nov 2, 2023 | 29 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Structure Therapeutics
Structure Therapeutics is a biopharmaceutical company based in South San Francisco, California. It is developing oral small molecule drugs that act on G protein coupled receptors, a family of receptors that control many body processes. Its most advanced candidate is aimed at obesity, and its pipeline includes other candidates for metabolic and related conditions. The company is still in clinical development, and its medicines are intended for patients with chronic diseases.
- Headquarters
- South San Francisco, CA


